Factor VIII-Fc Activates Natural Killer Cells
B-Lymphocytes
/ immunology
Cell Degranulation
Factor VIII
/ pharmacology
GPI-Linked Proteins
/ immunology
Hemostatics
/ pharmacology
Humans
Immune Tolerance
Immunoglobulin Fc Fragments
/ pharmacology
Interferon-gamma
/ immunology
Killer Cells, Natural
/ immunology
Receptors, IgG
/ immunology
Recombinant Fusion Proteins
/ pharmacology
Fc gamma receptors
Fc-fusion
antibody-dependent cellular cytotoxicity
immunogenicity
natural killer cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
04
2021
accepted:
16
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
26
10
2021
Statut:
epublish
Résumé
The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level <1%) hemophilia A (HA) patients and are a serious hindrance to effective management of HA. Consequently, strategies that can either prevent anti-FVIII inhibitors from developing or "tolerize" individuals who develop such antibodies represent a clinically important unmet need. One intervention for patients with high-titer inhibitors is immune tolerance induction (ITI) therapy. Although ITI therapy is the only clinically proven strategy to eradicate anti-FVIII inhibitors, mechanisms of inhibitor reduction remain unknown. Factor VIII Fc-fusion (rFVIIIFc) is an enhanced half-life antihemophilic factor used in replacement therapy for HA. Fc-fusion is a successful protein bio-engineering platform technology. In addition to enhancement of plasma half-life
Identifiants
pubmed: 34262568
doi: 10.3389/fimmu.2021.692157
pmc: PMC8273617
doi:
Substances chimiques
FCGR3B protein, human
0
GPI-Linked Proteins
0
Hemostatics
0
Immunoglobulin Fc Fragments
0
Receptors, IgG
0
Recombinant Fusion Proteins
0
factor VIII-Fc fusion protein
0
Interferon-gamma
82115-62-6
Factor VIII
9001-27-8
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
692157Informations de copyright
Copyright © 2021 Lagassé, Hopkins, Jankowski, Jacquemin, Sauna and Golding.
Déclaration de conflit d'intérêts
MJ reports grants from Bayer, Takeda, Pfizer and Sobi, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Haemophilia. 2010 Jan;16(1):3-13
pubmed: 19473409
Br J Haematol. 2010 Sep;150(5):515-28
pubmed: 20573153
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Blood. 2010 Jun 3;115(22):4393-402
pubmed: 20194898
J Am Chem Soc. 2013 Apr 24;135(16):6092-9
pubmed: 23544844
MAbs. 2011 Sep-Oct;3(5):415-6
pubmed: 21785279
Semin Hematol. 2010 Apr;47(2):115-23
pubmed: 20350658
Trends Biotechnol. 2015 Jan;33(1):27-34
pubmed: 25488117
Haemophilia. 2006 Jan;12(1):7-18
pubmed: 16409170
J Thromb Haemost. 2006 Oct;4(10):2271-3
pubmed: 16848866
Protein Cell. 2018 Jan;9(1):63-73
pubmed: 28986820
Blood. 2016 Oct 20;128(16):2007-2016
pubmed: 27587878
Haemophilia. 2016 Nov;22(6):e552-e554
pubmed: 27640873
Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
Adv Immunol. 2007;96:179-204
pubmed: 17981207
Crit Rev Biotechnol. 2015 Jun;35(2):235-54
pubmed: 24156398
N Engl J Med. 1988 Apr 14;318(15):947-50
pubmed: 3127711
Blood. 1997 Aug 1;90(3):1109-14
pubmed: 9242542
AAPS J. 2019 May 6;21(4):62
pubmed: 31062128
Pediatr Blood Cancer. 2016 May;63(5):922-4
pubmed: 26739399
Front Immunol. 2020 Feb 07;11:138
pubmed: 32117285
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
Int J Lab Hematol. 2017 May;39 Suppl 1:6-13
pubmed: 28447409
Br J Haematol. 2014 Jun;165(5):600-8
pubmed: 24628543
Nature. 2000 Jul 20;406(6793):267-73
pubmed: 10917521
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814660
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
Cell Immunol. 2016 Mar;301:30-9
pubmed: 26775174
Cancer Res. 2004 Jul 1;64(13):4664-9
pubmed: 15231679
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649
pubmed: 27913541
Acta Naturae. 2015 Apr-Jun;7(2):74-9
pubmed: 26085947
Blood. 1994 Jan 15;83(2):435-45
pubmed: 7506951
Blood. 2012 Mar 22;119(12):2922-34
pubmed: 22282501
Trends Immunol. 2015 Jun;36(6):325-36
pubmed: 25981969
Blood. 1995 Jun 1;85(11):3150-7
pubmed: 7756647
J Immunol Methods. 2014 Dec 1;414:69-81
pubmed: 25086226
Blood. 2012 Mar 29;119(13):3031-7
pubmed: 22223821
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Front Immunol. 2017 Nov 13;8:1544
pubmed: 29181007
Curr Opin Biotechnol. 2011 Dec;22(6):868-76
pubmed: 21862310
Nat Immunol. 2014 Aug;15(8):707-16
pubmed: 25045879
Blood. 2012 Mar 29;119(13):3024-30
pubmed: 22246033
J Clin Invest. 2019 Sep 3;129(9):3492-3498
pubmed: 31478910
Int Immunol. 2003 Jul;15(7):789-96
pubmed: 12807817
Hemasphere. 2020 Jan 03;4(1):e330
pubmed: 32072146
BioDrugs. 2015 Aug;29(4):215-39
pubmed: 26177629
Blood Adv. 2018 Nov 13;2(21):2904-2916
pubmed: 30396910
Blood. 2001 Jul 1;98(1):13-9
pubmed: 11418455
Haemophilia. 2018 Mar;24(2):245-252
pubmed: 29436077
J Thromb Haemost. 2009 Sep;7(9):1446-56
pubmed: 19583822
Blood. 1998 Jul 15;92(2):496-506
pubmed: 9657749
Exp Cell Res. 2011 May 15;317(9):1261-9
pubmed: 21371474
Mol Cancer Ther. 2006 Dec;5(12):3122-9
pubmed: 17172415
J Immunol Methods. 2005 Sep;304(1-2):88-99
pubmed: 16109421
Trends Biotechnol. 2018 Jul;36(7):686-699
pubmed: 29588069
PLoS One. 2011;6(6):e20991
pubmed: 21677771
Curr Med Chem. 2017;24(12):1228-1237
pubmed: 28088904
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092